Theravance Biopharma (NASDAQ:TBPH) Stock Rating Upgraded by Wall Street Zen

Theravance Biopharma (NASDAQ:TBPH) was upgraded by analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a research report issued on Sunday.

Several other equities research analysts have also recently commented on the company. BTIG Research boosted their price target on Theravance Biopharma from $25.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday, November 26th. HC Wainwright raised their price objective on Theravance Biopharma from $15.00 to $20.00 and gave the company a “buy” rating in a research note on Tuesday, November 11th. Zacks Research downgraded Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 15th. B. Riley started coverage on Theravance Biopharma in a research note on Friday, September 12th. They set a “buy” rating and a $28.00 target price for the company. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Theravance Biopharma in a research report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $27.80.

Theravance Biopharma Trading Up 2.8%

Shares of Theravance Biopharma stock opened at $18.17 on Friday. Theravance Biopharma has a 52 week low of $7.90 and a 52 week high of $20.33. The stock has a market cap of $920.67 million, a PE ratio of 31.88 and a beta of 0.14. The company’s 50-day moving average price is $16.34 and its two-hundred day moving average price is $13.63.

Theravance Biopharma (NASDAQ:TBPH) last issued its quarterly earnings results on Monday, November 10th. The biopharmaceutical company reported $0.07 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.10. The firm had revenue of $19.99 million for the quarter, compared to analysts’ expectations of $19.89 million. Theravance Biopharma had a return on equity of 12.20% and a net margin of 36.53%. On average, equities analysts predict that Theravance Biopharma will post -1.09 EPS for the current fiscal year.

Insiders Place Their Bets

In other Theravance Biopharma news, SVP Rhonda Farnum sold 31,067 shares of the stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $18.75, for a total transaction of $582,506.25. Following the completion of the transaction, the senior vice president owned 277,695 shares in the company, valued at approximately $5,206,781.25. This represents a 10.06% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 6.90% of the company’s stock.

Institutional Trading of Theravance Biopharma

Several institutional investors and hedge funds have recently bought and sold shares of the business. Tower Research Capital LLC TRC increased its position in Theravance Biopharma by 18.5% during the second quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock worth $55,000 after acquiring an additional 781 shares during the period. Creative Planning increased its position in Theravance Biopharma by 6.7% during the 3rd quarter. Creative Planning now owns 13,450 shares of the biopharmaceutical company’s stock valued at $196,000 after purchasing an additional 842 shares during the period. State of Wyoming raised its position in shares of Theravance Biopharma by 5.7% in the 2nd quarter. State of Wyoming now owns 18,928 shares of the biopharmaceutical company’s stock worth $209,000 after acquiring an additional 1,019 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in shares of Theravance Biopharma by 6.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,747 shares of the biopharmaceutical company’s stock valued at $174,000 after acquiring an additional 1,020 shares in the last quarter. Finally, Ballentine Partners LLC raised its stake in Theravance Biopharma by 9.3% during the 2nd quarter. Ballentine Partners LLC now owns 14,315 shares of the biopharmaceutical company’s stock worth $158,000 after buying an additional 1,221 shares during the period. Institutional investors own 99.10% of the company’s stock.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.